AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10332319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost occlusal appliances
Number of subjects: 0
Study 8486515 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin (1 g) with 2% lidocaine (3 ml)
Number of subjects: 20
Study 8486515 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone (3 ml)
Number of subjects: 20
Study 2444395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroid (flumethasone pivalate 0.02 percent)
Number of subjects: 30
Study 2444395 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution of eosin 2 percent
Number of subjects: 30
Study 30281180 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate at 50 mg kg-1
Number of subjects: 160
Study 30281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 3 μg kg-1 plus buccal midazolam at 0.1 mg kg-1
Number of subjects: 160
Study 30281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine plus buccal midazolam
Number of subjects: 160
Study 30281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study 27321983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained training group
Number of subjects: 0
Study 27321983 — intervention group
Group type: COMPARATOR
Intervention: Constrained training group
Number of subjects: 0
Study 25413281 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured rehabilitation after lumbar spine surgery
Number of subjects: 124
Study 23408867 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg octanoic acid (OA)
Number of subjects: 19
Study 23408867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20395941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) therapy with losartan
Number of subjects: 9193
Study 20395941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) therapy with atenolol
Number of subjects: 9193
Study 19018919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reminder on paper chart
Number of subjects: 194
Study 19018919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clinical reminder)
Number of subjects: 194
Study 21055945 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (TDCS) applied to the parietal lobes during numerical learning for 6 days.
Number of subjects: 0
Study 21055945 — intervention group
Group type: COMPARATOR
Intervention: Control tasks (not specified in detail).
Number of subjects: 0
Study 15704099 — intervention group
Group type: EXPERIMENTAL
Intervention: EFL group (40 teeth treated with fluoride gel and lased)
Number of subjects: 98
Study 15704099 — intervention group
Group type: EXPERIMENTAL
Intervention: EF group (40 teeth treated with fluoride gel)
Number of subjects: 98
Study 15704099 — intervention group
Group type: COMPARATOR
Intervention: E group (18 teeth untreated control)
Number of subjects: 98
Study 12417370 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (Reminyl®)
Number of subjects: 0
Study 9813986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 10 mg/kg/day orally for 14 days
Number of subjects: 40
Study 9813986 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 50 mg/kg/day orally for 14 days
Number of subjects: 40
Study 9813986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (after switching from chloramphenicol)
Number of subjects: 40
Study 9813986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime overall
Number of subjects: 40
Study 8071291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-250 mg/day)
Number of subjects: 66
Study 8071291 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (100-250 mg/day)
Number of subjects: 66
Study 8071291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 66
Study 8071291 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine and Clomipramine
Number of subjects: 66
Study 8071291 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 66
Study 3292598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study 3292598 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study 11310519 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 11310519 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine and Clopidogrel
Number of subjects: 0
Study 11310519 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and extended-release dipyridamole
Number of subjects: 0
Study 29908236 — intervention group
Group type: EXPERIMENTAL
Intervention: Retaliation against the outgroup during the cold-pressor task
Number of subjects: 0
Study 29908236 — intervention group
Group type: COMPARATOR
Intervention: No retaliation against the outgroup during the cold-pressor task
Number of subjects: 0
Study 27866195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT) 600 mg/d
Number of subjects: 130
Study 27866195 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) 0.5 mg/d
Number of subjects: 130
Study 24746916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy plus manual mobilizations
Number of subjects: 34
Study 24746916 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy only
Number of subjects: 34
Study 23328095 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI navigation
Number of subjects: 65
Study 23328095 — intervention group
Group type: COMPARATOR
Intervention: Routine operation without MRI navigation
Number of subjects: 65
Study 19924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum ADC
Number of subjects: 22
Study 19924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Average ADC
Number of subjects: 22
Study 19924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy values
Number of subjects: 22
Study 18385499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements using dual-energy x-ray absorptiometry
Number of subjects: 1
Study 16113133 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 12 weeks
Number of subjects: 38
Study 16113133 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 38
Study 12466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6.25 micro g/kg sc daily
Number of subjects: 10
Study 12466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) transdermal patch 5.0 mg/daily
Number of subjects: 10
Study 12466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Hormones (GHT)
Number of subjects: 10
Study 12466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 10
Study 12466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 10
Study 10526999 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS exposure at work
Number of subjects: 914
Study 10526999 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS exposure during leisure time
Number of subjects: 914
Study 10526999 — intervention group
Group type: COMPARATOR
Intervention: Unexposed to ETS
Number of subjects: 914
Study 8773292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FX)
Number of subjects: 462
Study 8773292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic Antidepressant (TCA)
Number of subjects: 462
Study 8773292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 462
Study 2268639 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative stomatological treatment with beta-adrenergic blocking agent 'Obsidan'
Number of subjects: 0
Study 2268639 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0
Study 85006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy as the only treatment
Number of subjects: 22
Study 85006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus local irradiation
Number of subjects: 22
Study 85006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Doxorubicin‐containing drug regimens)
Number of subjects: 22
Study 30722657 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint training in hypoxia (RSH)
Number of subjects: 12
Study 30722657 — intervention group
Group type: COMPARATOR
Intervention: Repeated-sprint training in normoxia (RSN)
Number of subjects: 12
Study 29951742 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL)
Number of subjects: 0
Study 29951742 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 26606200 — intervention group
Group type: EXPERIMENTAL
Intervention: 74-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Number of subjects: 313
Study 26606200 — intervention group
Group type: COMPARATOR
Intervention: 60-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Number of subjects: 313
Study 26606200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated RT (IMRT)
Number of subjects: 313
Study 26606200 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal RT (3D-CRT)
Number of subjects: 313
Study 25177682 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour EDD sessions
Number of subjects: 75
Study 25177682 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour EDD sessions
Number of subjects: 75
Study 25177682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 75
Study 23534328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, Minocycline, Metronidazole
Number of subjects: 25
Study 23534328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, Tinidazole, Minocycline
Number of subjects: 25
Study 20710094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program (NMTP) for 8 weeks
Number of subjects: 20
Study 20710094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NMTP) for 8 weeks
Number of subjects: 20
Study 17685720 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease supplement
Number of subjects: 20
Study 17685720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 20
Study 15807275 — intervention group
Group type: EXPERIMENTAL
Intervention: haiguiyuyang capsule
Number of subjects: 438
Study 15807275 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 438
Study 12072673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PL)
Number of subjects: 98
Study 12072673 — intervention group
Group type: COMPARATOR
Intervention: Ketamine with midazolam and fentanyl (KMF)
Number of subjects: 98
Study 11792284 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg/h)
Number of subjects: 51
Study 11792284 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (3 microgram/kg/h)
Number of subjects: 51
Study 11792284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9676901 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine (stage one)
Number of subjects: 36
Study 9676901 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine (stage two)
Number of subjects: 36
Study 9676901 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (stage one)
Number of subjects: 36
Study 9676901 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (stage two)
Number of subjects: 36
Study 9676901 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at breakfast
Number of subjects: 36
Study 9676901 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in fruit-juice (for subjects who had not had caffeine at breakfast)
Number of subjects: 36
Study 9676901 — intervention group
Group type: COMPARATOR
Intervention: Caffeine in stage one and stage two
Number of subjects: 36
Study 8141101 — intervention group
Group type: COMPARATOR
Intervention: Ftorafur, 400 mg/m2/day (Group A)
Number of subjects: 554
Study 8141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur, 400 mg/m2/day and Tamoxifen, 20 mg/day (Group B)
Number of subjects: 554
Study 3051673 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg twice a day)
Number of subjects: 32
Study 3051673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate (4 mg four times a day)
Number of subjects: 32
Study 3051673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acetazolamide and dexamethasone therapy
Number of subjects: 32
Study 3051673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 4938243 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (Lioresal)
Number of subjects: 23
Study 4938243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31937238 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (FLMA)
Number of subjects: 96
Study 31937238 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 96
Study 31389723 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention group
Number of subjects: 12866
Study 31389723 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 12866
Study 31389723 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-event composite
Number of subjects: 12866
Study 28545491 — intervention group
Group type: EXPERIMENTAL
Intervention: TESI plus Levobupivacaine added to oral pain medication
Number of subjects: 264
Study 28545491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injection (TEI) with Levobupivacaine and saline solution added to oral pain medication
Number of subjects: 264
Study 28545491 — intervention group
Group type: COMPARATOR
Intervention: Oral pain medication
Number of subjects: 264
Study 26408391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D volumetric models obtained from Cone Beam Computer Tomography (CBCT)
Number of subjects: 23
Study 23570446 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified formula of almond and olive oil, enriched with vitamin B1, B2, B6, E and fatty acids
Number of subjects: 164
Study 23570446 — intervention group
Group type: COMPARATOR
Intervention: Liquid wax (jojoba oil)
Number of subjects: 164
Study 23570446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oils (almond/olive oil and jojoba oil)
Number of subjects: 164
Study 21434843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontotemporoparietal decompressive craniectomy
Number of subjects: 155
Study 21434843 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 155
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + AS (35% phosphoric acid gel + adhesive system)
Number of subjects: 0
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + 10% NaOCl + AS
Number of subjects: 0
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + oxalate + AS
Number of subjects: 0
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + oxalate + 10% NaOCl + AS
Number of subjects: 0
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic acid alone
Number of subjects: 0
Study 19936527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% NaOCl alone or in combination with oxalic acid
Number of subjects: 0
Study 17014560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose tacrolimus (2 mg/day) and prednisone (30 mg/day)
Number of subjects: 60
Study 17014560 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (1 mg/kg per day)
Number of subjects: 60
Study 15232796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium diet
Number of subjects: 20
Study 15232796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Number of subjects: 20
Study 15232796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplement
Number of subjects: 20
Study 15232796 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐glutamine supplement
Number of subjects: 20
Study 15232796 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐cystine supplement
Number of subjects: 20
Study 11781679 — intervention group
Group type: COMPARATOR
Intervention: Glucose (G), n=71
Number of subjects: 138
Study 11781679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-fructose-xylitol 2:1:1 (GFX), n=67
Number of subjects: 138
Study 9577049 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 11
Study 9577049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8465162 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental Brigham knee prosthesis
Number of subjects: 59
Study 8465162 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy
Number of subjects: 59
Study 3802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally every six hours, beginning two days before lidocaine administration
Number of subjects: 6
Study 3802729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine hydrochloride 300 mg i.v. every six hours, beginning one hour before lidocaine administration
Number of subjects: 6
Study 3802729 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet every six hours, beginning two days before lidocaine administration
Number of subjects: 6
Study 31058534 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of NBPF1 gene in A431 cell line via plasmid transfection
Number of subjects: 1
Study 31058534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1
Study 29203583 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 27501015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal block (0.25% bupivacaine 0.5 mL/kg)
Number of subjects: 84
Study 27501015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal block
Number of subjects: 84
Study 27501015 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (0.2% bupivacaine 1 mL/kg)
Number of subjects: 84
Study 24316514 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg/kg/day for 48 hours)
Number of subjects: 1161
Study 24316514 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161
Study 24316514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study 22270738 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 120
Study 22270738 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic combined with nonparticulate betamethasone
Number of subjects: 120
Study 19737595 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hydrochloric acid gel (HCl) for 120s
Number of subjects: 32
Study 19737595 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel (H(3)PO(4)) for 120s
Number of subjects: 32
Study 17712577 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laminectomy (Group 1)
Number of subjects: 100
Study 17712577 — intervention group
Group type: COMPARATOR
Intervention: Unilateral laminotomy (Group 2)
Number of subjects: 100
Study 15832060 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated labeling pathway (ALP)
Number of subjects: 28
Study 12844393 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterostatin (ENT) 3 x 15 mg/d
Number of subjects: 12
Study 12844393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 12844393 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterostatin (ENT)
Number of subjects: 12
Study 10634196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alferon LDO
Number of subjects: 247
Study 10634196 — intervention group
Group type: EXPERIMENTAL
Intervention: Veldona
Number of subjects: 247
Study 10634196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferimmune
Number of subjects: 247
Study 10634196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 9166485 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (150 U/kg), subcutaneously, three times a week for 3 months
Number of subjects: 132
Study 9166485 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 3 months
Number of subjects: 132
Study 9166485 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 132
Study 9166485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 1718477 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine, 1 mg/kg
Number of subjects: 30
Study 1718477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone, 0.2 mg/kg
Number of subjects: 30
Study 1718477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 50 micrograms/kg
Number of subjects: 30
Study 7081040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (DBM) at 5 micrograms/kg/min
Number of subjects: 13
Study 7081040 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (DPM) at 5 micrograms/kg/min
Number of subjects: 13
Study 7081040 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (DPM) at 10 micrograms/kg/min
Number of subjects: 13
Study 3840189 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB-induced tan
Number of subjects: 5
Study 3840189 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA-induced tan
Number of subjects: 5
Study 28918108 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrecEF
Number of subjects: 318
Study 28918108 — intervention group
Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 318
Study 28243296 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 120
Study 28243296 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Number of subjects: 120
Study 28243296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24794475 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 173
Study 24794475 — intervention group
Group type: COMPARATOR
Intervention: Non-statin users
Number of subjects: 173
Study 23018655 — intervention group
Group type: EXPERIMENTAL
Intervention: etafilcon A lenses
Number of subjects: 30
Study 20421333 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day)
Number of subjects: 28